Drugs / XNW4107
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04801043 | Mar → Oct 2021 | bacterial infectious disease | Evopoint Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04787562 | Feb → Oct 2021 | bacterial infectious disease | Evopoint Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04482569 | Jul 2020 → Feb 2021 | bacterial infectious disease | Evopoint Biosciences Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05204368 | Mar 2023 → Jun 2025 | acute pyelonephritis | Evopoint Biosciences Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05204563 | Jul 2022 → Sep 2024 | bacterial pneumonia | Evopoint Biosciences Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW4107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04482569 ↗ |
| Route | Intravenous | “given as intravenous (IV) infusion” NCT04482569 ↗ |